Fritextsökning
Artiklar per år
Innehållstyper
-
”Bilder är det perfekta målet för AI”
Allt fler lösningar baserade på artificiell intelligens utvecklas och används i vården. Radiologi är ett område som lämpar sig väl för tekniken. Det menar Sophia Zackrisson, professor i radiologi vid Lunds universitet.
-
Stor kongress om framtidsutsikter igång i Lund
Vad sker i framtiden inom svensk och dansk life science? Det diskuteras i dag vid eventet The Future of Swedish and Danish Life Science i Lund.
-
Bioarctic går vidare med parkinsonkandidat efter lyckad fas I-studie
Bioarctic meddelar positiva studieresultat i tidig klinisk fas för sin läkemedelskandidat mot Parkinsons sjukdom.
-
Studie bekräftar god effekt av ebolavaccin
En ny studie ger ökat hopp om att kunna tygla den dödliga sjukdomen ebola. Data visar att vaccinering minskar risken för att insjukna med 84 procent.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be respected, to not have their identity overshadowed by their condition”, writes Anna Törner
-
Danish biotech to buy struggling American oncology company
Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.
-
Kvinnohälsa en outnyttjad marknad – ”Det finns goda kommersiella möjligheter”
Mer och mer sker inom området kvinnohälsa när det kommer till både innovation och investeringar. Förutom att vara en viktig marknad är det även en relativt outnyttjad marknad, menar Charlotte Nørgaard Langer.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Investeraren: ”De stora folksjukdomarna är heta igen”
Hon har tidigare utsetts till Årets investerare och ska nu moderera kongressen The Future of Swedish & Danish Life Science. Vi tar tempen på branschen med Nina Rawal från Trill Impact Advisory.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Healthcare study: Alzheimer’s blood test shows high accuracy
A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.
-
Fullt godkännande i EU för Calliditas njurläkemedel – "Viktig händelse"
Calliditas läkemedel Kinpeygo har fått ett fullständigt godkännande från EU-kommissionen för behandling av vuxna med njursjukdomen IgA-nefropati, IgAN.
-
Tummen ned för lecanemab i EU – ”Jätteförvånad”
Alzheimerläkemedlet lecanemab får ett negativ utlåtande från den europeiska läkemedelsmyndighetens kommitté för humanläkemedel, CHMP. Det meddelade myndigheten i förra veckan. Förvåning och besvikelse, så beskriver Bioarctics vd Gunilla Osswald reaktionerna efter beskedet.
-
Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”
Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her opening speech in the Swedish pavilion at the ReBuild Ukraine fair.
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other industries for inspiration and knowledge.
-
Ranking: Top 10 highest-paid CEOs in pharma
It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the best paid CEOs in Big Pharma 2023.
-
Danish obesity success causes recruitment problems in southern Sweden
The substantial expansion of Danish Novo Nordisk is affecting companies in southern Sweden, which are finding it increasingly difficult to compete for attractive staff.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be attached to the product information and patients to be followed up for life.
-
Uppsalabolag prisas för utveckling av snabbtest för antibiotikaresistens
Uppsalabolaget Sysmex Astrego prisas för sitt antibiotikakänslighetstest. Företaget tilldelades under onsdagen the Longitude Prize och får ta emot 8 miljoner pund.
-
Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”
The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from ABBA songs, turns 30 this year. "There is great interest in Sweden and Swedish solutions globally," says Anna Redwood from Business Sweden.
-
Bio Europe intar Stockholm i höst – ”Det svenska ekosystemet tar nu tillfället i akt”
Den internationella life science-konferensen Bio Europe kommer i november för första gången till Sverige. Konferensen, vars program tar inspiration av ABBA-låtar, fyller i år 30. ”Det finns ett stort intresse för Sverige och svenska lösningar globalt”, säger Anna Redwood från Business Sweden.
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Sofia Wallström is Lif's new CEO
Sofia Wallström has been appointed as the new CEO of the industry organization Lif, the trade association for the research-based pharmaceutical industry in Sweden.
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 100 years old, he looks back on an intense life and his upbringing in Stockholm, Sweden, which shaped his desire to help the vulnerable in society.